Dynamic microbiome and metabolome analyses reveal the interaction between gut microbiota and anti‐PD‐1 based immunotherapy in hepatocellular carcinoma
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Cancer"
DOI: 10.1002/ijc.34118
Abstract: Hepatocellular carcinoma (HCC) is a severe disease with high mortality and global incidence. However, the interaction between the gut microbiome and combined immunotherapy for HCC is yet unclear. In this prospective clinical study, patients with… read more here.
Keywords: hepatocellular carcinoma; gut; interaction gut; based immunotherapy ... See more keywords
Anti–PD-1 and Anti–PD-L1 in Head and Neck Cancer: A Network Meta-Analysis
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2021.705096
Abstract: Objective The monoclonal antibodies anti-programmed death protein-1 (anti–PD-1) nivolumab and pembrolizumab are the first immune checkpoint inhibitors (ICIs) approved for treatment of recurrent/metastatic head and neck carcinoma R/M HNSCC in first line and in platinum… read more here.
Keywords: anti based; based therapy; network meta; meta analysis ... See more keywords
Role of a Modified Urothelium Immune Prognostic Index in Patients With Metastatic Urothelial Carcinoma Treated With Anti–PD-1/PD-L1–Based Therapy
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Molecular Biosciences"
DOI: 10.3389/fmolb.2021.621883
Abstract: Introduction: The use of antibodies against programmed death receptor-1 (PD-1) and its ligand (PD-L1) has improved survival in metastatic urothelial carcinoma (mUC) patients. However, reliable and convenient biomarkers of early responses and outcomes are still… read more here.
Keywords: anti based; muc patients; urothelial carcinoma; muipi ... See more keywords
High farnesoid X receptor expression predicts favorable clinical outcomes in PD-L1low/negative non-small cell lung cancer patients receiving anti-PD-1-based chemo-immunotherapy
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Oncology"
DOI: 10.3892/ijo.2022.5330
Abstract: Anti-programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1)-directed immunotherapy has revolutionized the treatment of advanced non-small cell lung cancer (NSCLC). However, predictive biomarkers are still lacking, particularly in identifying PD-L1low/negative patients who will benefit from immunotherapy. It… read more here.
Keywords: l1low negative; immunotherapy; based chemo; expression ... See more keywords